Waters Corporation filings document operating results, proxy governance, capital-structure changes, material agreements, and corporate events for a NYSE-listed life sciences and diagnostics company. Recent 8-K reports include quarterly and annual results, exhibits furnished with earnings releases, and disclosure tied to the completed combination with BD’s Biosciences and Diagnostic Solutions business.
The company’s SEC record also covers senior unsecured notes issued by Augusta SpinCo Corporation and guaranteed by Waters and certain subsidiaries, pro forma and combined financial information for the acquired business, and definitive proxy materials addressing board oversight, shareholder voting matters, executive compensation, and governance practices.
Waters Corp director Christopher A. Kuebler reported equity awards that increase his direct holdings. On February 25, 2026, he received a stock option for 57 shares at an exercise price of $0.00 per share and a grant of 23 shares of common stock at $0.00 per share.
The 23 common shares are subject to restrictions that lapse for all shares on February 9, 2027, and all 57 option shares vest and become exercisable on the same date. Following the stock grant, Kuebler directly owns 17,808 shares of Waters common stock.
Waters Corporation director Heather Knight reported awards of both stock options and restricted common shares. She received stock options for 57 shares at an exercise price of $0.0000 per share and a grant of 23 common shares, all as awards rather than open-market purchases.
The 23 common shares are subject to restrictions that lapse for all of the shares on February 9, 2027. All 57 option shares will vest and become exercisable on February 9, 2027. After these grants, her directly owned common shares total 1,149.070.
Waters Corporation director Jiang Wei reported receiving new equity awards. He acquired 23 shares of common stock at no cost, which are subject to restrictions that lapse in full on February 9, 2027. He was also granted a stock option for 57 shares that becomes fully exercisable on February 9, 2027. Both positions are held as direct ownership.
Waters Corporation director Pearl S. Huang reported receiving new equity awards. On February 25, 2026, she was granted stock options for 57 shares of common stock at an exercise price of $0.00 per share. All of these option shares will vest and become exercisable on February 9, 2027.
On the same date, she also acquired 23 shares of common stock at $0.00 per share as a restricted stock award. The restrictions on 100% of these shares are scheduled to lapse on February 9, 2027. Following these awards, her directly held common stock position increased to 3,276.3 shares.
Waters Corporation director Claire Fraser reported equity awards consisting of stock options and restricted common shares. On February 25, 2026, she was granted options for 877 shares of common stock at an exercise price of $0.0000 per share and 358 shares of common stock at no cost, both as awards rather than open-market purchases.
According to the disclosures, all 358 common shares are subject to restrictions that lapse on February 9, 2027. The 877 stock options will fully vest and become exercisable on the same date, aligning Fraser’s longer-term incentives with Waters’ future performance.
Waters Corporation director Richard H. Fearon reported awards of stock-based compensation. On February 25, 2026, he acquired a stock option covering 57 shares of common stock at an exercise price of $0.00 per share, which will vest and become exercisable on February 9, 2027.
He also received 23 shares of restricted common stock at no cost, subject to restrictions that lapse in full on February 9, 2027. Following these awards, he directly owned 2,302 shares of Waters common stock.
Waters Corporation director Daniel J. Brennan reported equity awards that increase his direct ownership in the company. He received a stock option covering 57 shares of common stock at an exercise price of $0.00 per share, and a grant of 23 shares of restricted common stock, both on February 25, 2026.
The restricted shares remain subject to restrictions until February 9, 2027, when they fully lapse. All 57 option shares will vest and become exercisable on the same February 9, 2027 date. Following these grants, Brennan directly owns 1,355 shares of Waters common stock.
Waters Corp director Linda Baddour reported receiving new equity awards. On February 25, 2026, she acquired stock options for 57 shares of common stock at an exercise price of $0.00 per share and 23 shares of common stock granted at no cost.
All 57 option shares and the 23 restricted common shares vest on February 9, 2027. Following these grants, she directly holds 2,899 shares of common stock and 57 stock options in Waters Corp.
Ornskov Flemming reported acquisition or exercise transactions in this Form 4 filing.
Waters Corp director Flemming Ornskov reported equity awards, not open-market trades. On February 25, 2026, he received a grant of 336 shares of common stock at no cash cost, increasing his directly held common shares to 5,271.
He also received a stock option for 57 shares at no cash cost. According to the footnotes, the 336-share award is subject to restrictions that lapse on February 9, 2027, and all 57 option shares will vest and become exercisable on February 9, 2027.
Waters Corporation filed its annual report describing a major expansion and evolving risk profile. The company remains a global leader in liquid chromatography, mass spectrometry and thermal analysis, serving pharmaceutical, industrial, academic and government customers, with 59% of 2025 net sales from pharmaceutical accounts and 69% of sales generated outside the U.S.
The centerpiece is the $16.8 billion acquisition of BD’s Biosciences and Diagnostic Solutions businesses, structured as a Reverse Morris Trust. BD shareholders now own about 39.2% of the combined company and Waters shareholders 60.8%. Management projects approximately $200 million in cost synergies within three years and $290 million in revenue synergies within five years, alongside restructuring of manufacturing, supply chain and commercial infrastructure.
Waters assumed $4.0 billion of new debt through SpinCo, on top of $1.4 billion outstanding as of December 31, 2025, and plans to refinance a $3.5 billion tranche in early 2026. The report highlights integration challenges, higher leverage, restrictions under a Tax Matters Agreement, macroeconomic and China-related demand risks, competitive pressures, product quality and AI-related risks, but underscores continued investment in R&D, new instruments and software, and a broad, diversified customer base.